retatrutide pronounce Avoid mispronouncing the name of this weight loss drug, Everything you need to know

[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis

A substudy examining participants with metabolic-associated steatotic liver disease produced results that no pharmacological intervention had previously achieved

There was no significant change in BMI within the exenatide group at 12 weeks, indicating that the effect on intracranial pressure was not driven by reduction in body weight, but likely by direct effect of exenatide to modulate intracranial pressure at the choroid plexus

This helps the provider determine your target dose

Clinical studies on FDA-approved GLP-1 receptor agonists have shown that the most significant weight loss typically occurs between 16 and 48 weeks of consistent use